239 related articles for article (PubMed ID: 11374699)
1. High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis.
Harnois DM; Angulo P; Jorgensen RA; Larusso NF; Lindor KD
Am J Gastroenterol; 2001 May; 96(5):1558-62. PubMed ID: 11374699
[TBL] [Abstract][Full Text] [Related]
2. High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective.
Cullen SN; Rust C; Fleming K; Edwards C; Beuers U; Chapman RW
J Hepatol; 2008 May; 48(5):792-800. PubMed ID: 18314215
[TBL] [Abstract][Full Text] [Related]
3. Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial.
Färkkilä M; Karvonen AL; Nurmi H; Nuutinen H; Taavitsainen M; Pikkarainen P; Kärkkäinen P
Hepatology; 2004 Dec; 40(6):1379-86. PubMed ID: 15565569
[TBL] [Abstract][Full Text] [Related]
4. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study.
Olsson R; Boberg KM; de Muckadell OS; Lindgren S; Hultcrantz R; Folvik G; Bell H; Gangsøy-Kristiansen M; Matre J; Rydning A; Wikman O; Danielsson A; Sandberg-Gertzén H; Ung KA; Eriksson A; Lööf L; Prytz H; Marschall HU; Broomé U
Gastroenterology; 2005 Nov; 129(5):1464-72. PubMed ID: 16285948
[TBL] [Abstract][Full Text] [Related]
5. Ursodeoxycholic acid and methotrexate for primary sclerosing cholangitis: a pilot study.
Lindor KD; Jorgensen RA; Anderson ML; Gores GJ; Hofmann AF; LaRusso NF
Am J Gastroenterol; 1996 Mar; 91(3):511-5. PubMed ID: 8633500
[TBL] [Abstract][Full Text] [Related]
6. Incomplete response to ursodeoxycholic acid in primary biliary cirrhosis: is a double dosage worthwhile?
Angulo P; Jorgensen RA; Lindor KD
Am J Gastroenterol; 2001 Nov; 96(11):3152-7. PubMed ID: 11721764
[TBL] [Abstract][Full Text] [Related]
7. Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: a randomized double-blind pilot study. Belgian-Dutch PSC Study Group.
van Hoogstraten HJ; Vleggaar FP; Boland GJ; van Steenbergen W; Griffioen P; Hop WC; van Hattum J; van Berge Henegouwen GP; Schalm SW; van Buuren HR
Am J Gastroenterol; 2000 Aug; 95(8):2015-22. PubMed ID: 10950051
[TBL] [Abstract][Full Text] [Related]
8. Oral budesonide in the treatment of primary sclerosing cholangitis.
Angulo P; Batts KP; Jorgensen RA; LaRusso NA; Lindor KD
Am J Gastroenterol; 2000 Sep; 95(9):2333-7. PubMed ID: 11007238
[TBL] [Abstract][Full Text] [Related]
9. High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia.
Lindström L; Boberg KM; Wikman O; Friis-Liby I; Hultcrantz R; Prytz H; Sandberg-Gertzén H; Sangfelt P; Rydning A; Folvik G; Gangsøy-Kristiansen M; Danielsson A; Bergquist A
Aliment Pharmacol Ther; 2012 Feb; 35(4):451-7. PubMed ID: 22221173
[TBL] [Abstract][Full Text] [Related]
10. Natural history of pruritus in primary biliary cirrhosis.
Talwalkar JA; Souto E; Jorgensen RA; Lindor KD
Clin Gastroenterol Hepatol; 2003 Jul; 1(4):297-302. PubMed ID: 15017671
[TBL] [Abstract][Full Text] [Related]
11. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group.
Lindor KD
N Engl J Med; 1997 Mar; 336(10):691-5. PubMed ID: 9041099
[TBL] [Abstract][Full Text] [Related]
12. Meta-analysis: ursodeoxycholic acid for primary sclerosing cholangitis.
Triantos CK; Koukias NM; Nikolopoulou VN; Burroughs AK
Aliment Pharmacol Ther; 2011 Oct; 34(8):901-10. PubMed ID: 21883323
[TBL] [Abstract][Full Text] [Related]
13. Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid.
Angulo P; Patel T; Jorgensen RA; Therneau TM; Lindor KD
Hepatology; 2000 Nov; 32(5):897-900. PubMed ID: 11050036
[TBL] [Abstract][Full Text] [Related]
14. Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis.
Lindström L; Hultcrantz R; Boberg KM; Friis-Liby I; Bergquist A
Clin Gastroenterol Hepatol; 2013 Jul; 11(7):841-6. PubMed ID: 23353641
[TBL] [Abstract][Full Text] [Related]
15. Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome.
Floreani A; Rizzotto ER; Ferrara F; Carderi I; Caroli D; Blasone L; Baldo V
Am J Gastroenterol; 2005 Jul; 100(7):1516-22. PubMed ID: 15984974
[TBL] [Abstract][Full Text] [Related]
16. [Primary sclerosing cholangitis: conventional and quantitative liver function tests during long-term therapy with ursodeoxycholic acid].
Schönfeld J; Zotz R; Mahl M; Beste M; Breuer N; Goebell H
Z Gastroenterol; 1996 Feb; 34(2):123-7. PubMed ID: 8659187
[TBL] [Abstract][Full Text] [Related]
17. Tacrolimus for the treatment of primary sclerosing cholangitis.
Talwalkar JA; Gossard AA; Keach JC; Jorgensen RA; Petz JL; Lindor RN
Liver Int; 2007 May; 27(4):451-3. PubMed ID: 17403184
[TBL] [Abstract][Full Text] [Related]
18. Effect of high-dose ursodeoxycholic acid on its biliary enrichment in primary sclerosing cholangitis.
Rost D; Rudolph G; Kloeters-Plachky P; Stiehl A
Hepatology; 2004 Sep; 40(3):693-8. PubMed ID: 15349909
[TBL] [Abstract][Full Text] [Related]
19. Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis.
Wunsch E; Trottier J; Milkiewicz M; Raszeja-Wyszomirska J; Hirschfield GM; Barbier O; Milkiewicz P
Hepatology; 2014 Sep; 60(3):931-40. PubMed ID: 24519384
[TBL] [Abstract][Full Text] [Related]
20. Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: a randomized placebo-controlled treatment trial.
Czaja AJ; Carpenter HA; Lindor KD
Hepatology; 1999 Dec; 30(6):1381-6. PubMed ID: 10573515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
